Witty still looking for $1-2 billion 'bolt-ons' and scorns 'ghost' stories on price hikes
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's CEO Andrew Witty has told Scrip that although the company is still looking for the right deal at the right price in India, it is not very keen on a large acquisition, preferring what he termed "bolt-on" deals.